DK2672957T3 - Hidtil ukendt sammensætning til behandling af cystisk fibrose - Google Patents

Hidtil ukendt sammensætning til behandling af cystisk fibrose Download PDF

Info

Publication number
DK2672957T3
DK2672957T3 DK12704027.7T DK12704027T DK2672957T3 DK 2672957 T3 DK2672957 T3 DK 2672957T3 DK 12704027 T DK12704027 T DK 12704027T DK 2672957 T3 DK2672957 T3 DK 2672957T3
Authority
DK
Denmark
Prior art keywords
treatment
cystic fibrosis
hitherto unknown
unknown composition
composition
Prior art date
Application number
DK12704027.7T
Other languages
English (en)
Inventor
Christina Gloeckel
Simon Keuerleber
Michael Freissmuth
Xaver Koenig
Original Assignee
Scipharm Sàrl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799687&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2672957(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scipharm Sàrl filed Critical Scipharm Sàrl
Application granted granted Critical
Publication of DK2672957T3 publication Critical patent/DK2672957T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK12704027.7T 2011-02-07 2012-02-03 Hidtil ukendt sammensætning til behandling af cystisk fibrose DK2672957T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11153541 2011-02-07
PCT/EP2012/051880 WO2012107363A1 (en) 2011-02-07 2012-02-03 Novel composition for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
DK2672957T3 true DK2672957T3 (da) 2017-02-06

Family

ID=43799687

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12704027.7T DK2672957T3 (da) 2011-02-07 2012-02-03 Hidtil ukendt sammensætning til behandling af cystisk fibrose

Country Status (27)

Country Link
US (1) US9504663B2 (da)
EP (1) EP2672957B1 (da)
JP (2) JP5997182B2 (da)
KR (1) KR101852222B1 (da)
CN (1) CN103391766B (da)
AU (1) AU2012215606B2 (da)
BR (1) BR112013019335B1 (da)
CA (1) CA2826183C (da)
CL (1) CL2013002234A1 (da)
CY (1) CY1119999T1 (da)
DK (1) DK2672957T3 (da)
EA (1) EA029760B1 (da)
ES (1) ES2612510T3 (da)
HR (1) HRP20170113T1 (da)
HU (1) HUE031652T2 (da)
IL (1) IL227738B (da)
LT (1) LT2672957T (da)
ME (1) ME02598B (da)
PL (1) PL2672957T3 (da)
PT (1) PT2672957T (da)
RS (1) RS55624B1 (da)
SG (1) SG192677A1 (da)
SI (1) SI2672957T1 (da)
SM (2) SMT201700099T1 (da)
UA (1) UA113161C2 (da)
WO (1) WO2012107363A1 (da)
ZA (1) ZA201305276B (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
CN111108109A (zh) 2017-09-20 2020-05-05 利奥制药有限公司 取代的二氢噻吩并嘧啶及其作为磷酸二酯酶抑制剂的用途
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
DK3724196T3 (da) * 2017-12-15 2023-01-16 Union Therapeutics As Substituerede azetidindihydrothienopyridiner og anvendelse deraf som phosphodiesterasehæmmere
WO2020201915A2 (en) * 2019-03-24 2020-10-08 Aribio Co., Ltd. Compositions and methods for reducing amyloid beta formation on and composition therefore
CN113244395B (zh) * 2020-02-10 2024-07-23 广州市妇女儿童医疗中心 纤维化疾病机制及其治疗药物
JP2023553290A (ja) * 2020-12-01 2023-12-21 リバースパ エルエルシー 慢性閉塞性肺疾患、喘息、肺炎、気管支炎、嚢胞性線維症、肺水腫、間質性肺疾患、サルコイドーシス、特発性肺胞線維症、急性呼吸窮迫症候群、および肺動脈性肺高血圧症を治療するための方法および組成物
CN116887829A (zh) * 2021-01-29 2023-10-13 美迪诺亚公司 治疗化学气体暴露的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3409029B2 (ja) * 1997-10-03 2003-05-19 メルク フロスト カナダ アンド カンパニー Ｐｄｅｉｖ阻害剤としてのアリールチオフェン誘導体
US6020339A (en) 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US20010006979A1 (en) 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
CA2364653A1 (en) 1999-02-25 2000-08-31 Merck Frosst Canada & Co. Pde iv inhibiting compounds, compositions and methods of treatment
US6436965B1 (en) 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
EE200300514A (et) 2001-04-25 2004-02-16 Altana Pharma Ag Ftalasinoonid, nende kasutamine hingamisteede haigusnähte leevendavate ravimite valmistamiseks ningneid sisaldavad ravimid
AU2002330747B2 (en) 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
TWI347845B (en) 2002-03-06 2011-09-01 Nycomed Gmbh Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2004067006A1 (en) 2003-01-27 2004-08-12 Pharmacia Corporation Combination of a pde iv inhibitor and a tnf-alpha antagonist
US20050101608A1 (en) 2003-09-24 2005-05-12 Santel Donald J. Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
EP1796653A2 (en) 2004-07-26 2007-06-20 Actelion Pharmaceuticals Ltd. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
DE102005016345A1 (de) 2005-04-09 2006-10-12 Bayer Healthcare Ag Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
US7893050B2 (en) 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
US8084221B2 (en) * 2006-04-01 2011-12-27 Saint Louis University Method of screening for a drug candidate that increases ATP release from RBCs stimulated via the Gs or Gi pathway
FR2903693B1 (fr) 2006-07-17 2012-03-30 Inst Nat Polytech Grenoble Sulfinates et halogenures de sulfonyle aromatiques, et leur preparation.
US20090325976A1 (en) * 2006-12-21 2009-12-31 Concert Pharmaceuticals Inc. Prostacyclin derivatives
WO2008079383A1 (en) 2006-12-21 2008-07-03 Concert Pharmaceuticals Inc. Prostacyclin derivatives
US20080280986A1 (en) * 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
US20100179158A1 (en) * 2007-04-20 2010-07-15 Hoffman Charles S Inhibitors of cyclic amp phosphodiesterases
WO2010106494A1 (en) * 2009-03-20 2010-09-23 H.L. Hall & Sons Limited Use of pharmaceutical compositions containing mesembrenone
US20120184622A1 (en) 2009-08-07 2012-07-19 Scipharm Sarl Composition for the treatment of cystic fibrosis
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung

Also Published As

Publication number Publication date
IL227738B (en) 2019-05-30
JP5997182B2 (ja) 2016-09-28
SMT201700099T1 (it) 2017-03-08
WO2012107363A1 (en) 2012-08-16
JP2014505082A (ja) 2014-02-27
AU2012215606A1 (en) 2013-08-01
KR101852222B1 (ko) 2018-04-25
CA2826183A1 (en) 2012-08-16
US20140018430A1 (en) 2014-01-16
EP2672957A1 (en) 2013-12-18
PL2672957T3 (pl) 2017-05-31
AU2012215606B2 (en) 2016-12-22
EA201300892A1 (ru) 2013-12-30
RS55624B1 (sr) 2017-06-30
JP2016199574A (ja) 2016-12-01
SMT201700099B (it) 2017-03-08
US9504663B2 (en) 2016-11-29
SG192677A1 (en) 2013-09-30
ES2612510T3 (es) 2017-05-17
BR112013019335A2 (pt) 2020-10-27
CY1119999T1 (el) 2018-12-12
IL227738A0 (en) 2013-09-30
UA113161C2 (xx) 2016-12-26
KR20140007865A (ko) 2014-01-20
NZ613118A (en) 2015-06-26
EA029760B1 (ru) 2018-05-31
BR112013019335B1 (pt) 2022-05-31
CA2826183C (en) 2019-05-14
HUE031652T2 (en) 2017-07-28
HRP20170113T1 (hr) 2017-03-24
SI2672957T1 (sl) 2017-03-31
ME02598B (me) 2017-06-20
EP2672957B1 (en) 2016-11-02
ZA201305276B (en) 2014-09-25
CN103391766A (zh) 2013-11-13
CN103391766B (zh) 2018-05-25
CL2013002234A1 (es) 2014-01-03
LT2672957T (lt) 2017-02-10
PT2672957T (pt) 2017-01-31

Similar Documents

Publication Publication Date Title
DK2461812T3 (da) Præparat til behandling af cystisk fibrose
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
SMT201600271B (it) BENZOSSAZEPINONI FUSI COME MODULATORI DI CANALl IONICI
EP2675909A4 (en) GLUCOSYLSTEVIA COMPOSITION
EP2720561A4 (en) Stevia-COMPOSITION
EP2713762A4 (en) Stevia-COMPOSITION
IL227514A0 (en) Rebaudioside-mogroside v blends
DK2718404T3 (da) Fremgangsmåde til fremstilling af flydende carbonhydrider
LT2742151T (lt) Polimerazės kompozicija
BR112013022112A2 (pt) composição
PL2672957T3 (pl) Nowe kompozycje do leczenia mukowiscydozy
DK2686017T3 (da) Oftalmisk sammensætning
BR112014004395A2 (pt) composição
DK2730310T3 (da) Applikator
DK2635282T3 (da) Sammensætninger til behandling af myelofibrose
DK3021839T3 (da) Sammensætninger for behandling af fibrose
EP2737924A4 (en) APPLICATOR
EP2755229A4 (en) Dry etching method
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
BR112013033808A2 (pt) composição
EP2723955A4 (en) Formwork support improvements
EP2730619A4 (en) COMPOSITION
EP2702895A4 (en) APPLICATOR
PT2739276T (pt) Composição antisséptica
EP2722366A4 (en) CURABLE COMPOSITION